Latest Insider Transactions at Ptc Therapeutics, Inc. (PTCT)
This section provides a real-time view of insider transactions for Ptc Therapeutics, Inc. (PTCT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PTC THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PTC THERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 12
2026
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,024
-1.26%
|
$79,872
$78.7 P/Share
|
|
Jan 09
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
2,314
-0.68%
|
$180,492
$78.56 P/Share
|
|
Jan 09
2026
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,722
-2.08%
|
$132,594
$77.41 P/Share
|
|
Jan 08
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
59
-0.86%
|
$4,484
$76.45 P/Share
|
|
Jan 08
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
881
-0.76%
|
$66,956
$76.45 P/Share
|
|
Jan 08
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
4,033
-1.15%
|
$306,508
$76.69 P/Share
|
|
Jan 08
2026
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
866
-0.93%
|
$65,816
$76.45 P/Share
|
|
Jan 08
2026
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
2,514
-0.63%
|
$191,064
$76.45 P/Share
|
|
Jan 08
2026
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
4,602
-1.78%
|
$349,752
$76.62 P/Share
|
|
Jan 08
2026
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,034
-1.4%
|
$78,584
$76.45 P/Share
|
|
Jan 07
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
52
-0.75%
|
$4,004
$77.48 P/Share
|
|
Jan 07
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,026
-0.88%
|
$79,002
$77.48 P/Share
|
|
Jan 07
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
4,879
-0.58%
|
$375,683
$77.87 P/Share
|
|
Jan 07
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,376
+1.38%
|
$128,288
$38.1 P/Share
|
|
Jan 07
2026
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
642
-0.68%
|
$49,434
$77.48 P/Share
|
|
Jan 07
2026
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,016
-0.75%
|
$232,232
$77.48 P/Share
|
|
Jan 07
2026
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,352
-1.52%
|
$104,104
$77.48 P/Share
|
|
Jan 07
2026
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,235
-1.65%
|
$95,095
$77.45 P/Share
|
|
Jan 06
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
54
-0.78%
|
$4,104
$76.95 P/Share
|
|
Jan 06
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,279
-1.08%
|
$97,204
$76.95 P/Share
|
|
Jan 06
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
1,739
-1.44%
|
$132,164
$76.95 P/Share
|
|
Jan 06
2026
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,340
-1.41%
|
$101,840
$76.95 P/Share
|
|
Jan 06
2026
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
5,149
-1.27%
|
$391,324
$76.95 P/Share
|
|
Jan 06
2026
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,789
-1.97%
|
$135,964
$76.95 P/Share
|
|
Jan 06
2026
|
Pierre Gravier CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,139
-2.31%
|
$162,564
$76.95 P/Share
|
|
Jan 06
2026
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,381
-1.81%
|
$104,956
$76.95 P/Share
|
|
Jan 05
2026
|
Emma Reeve |
SELL
Open market or private sale
|
Direct |
734
-6.44%
|
$55,784
$76.0 P/Share
|
|
Jan 05
2026
|
Emma Reeve |
BUY
Exercise of conversion of derivative security
|
Direct |
734
+6.05%
|
$33,764
$46.54 P/Share
|
|
Jan 05
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
2,266
-0.62%
|
$169,950
$75.94 P/Share
|
|
Jan 05
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,266
+1.81%
|
$88,374
$39.42 P/Share
|
|
Jan 02
2026
|
Glenn Jr Md Phd Steele |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+15.09%
|
-
|
|
Jan 02
2026
|
Glenn Jr Md Phd Steele |
SELL
Open market or private sale
|
Direct |
12,000
-39.34%
|
$912,000
$76.35 P/Share
|
|
Jan 02
2026
|
Glenn Jr Md Phd Steele |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+28.24%
|
$360,000
$30.86 P/Share
|
|
Jan 02
2026
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
63,000
+13.46%
|
-
|
|
Jan 02
2026
|
Pierre Gravier CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+17.79%
|
-
|
|
Jan 02
2026
|
Michael Schmertzler |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+4.67%
|
-
|
|
Jan 02
2026
|
Allan Steven Jacobson |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+15.72%
|
-
|
|
Jan 02
2026
|
Stephanie Okey |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+25.0%
|
-
|
|
Jan 02
2026
|
David P Southwell |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+16.1%
|
-
|
|
Jan 02
2026
|
Alethia Young |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+15.96%
|
-
|
|
Jan 02
2026
|
Jerome B Zeldis |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+15.09%
|
-
|
|
Jan 02
2026
|
Emma Reeve |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+27.27%
|
-
|
|
Jan 02
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+12.33%
|
-
|
|
Jan 02
2026
|
Eric Pauwels CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+18.08%
|
-
|
|
Jan 02
2026
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+16.44%
|
-
|
|
Jan 02
2026
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,250
+14.79%
|
-
|
|
Jan 02
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
BUY
Grant, award, or other acquisition
|
Indirect |
520
+6.96%
|
-
|
|
Jan 02
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+12.88%
|
-
|
|
Jan 02
2026
|
Mary L. Smith |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+15.5%
|
-
|
|
Dec 30
2025
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
8,089
-2.31%
|
$614,764
$76.64 P/Share
|